Quantum-Si has demonstrated detection of all 20 naturally occurring amino acids in its Proteus development program, achieving its year-end 2026 goal ahead of schedule. It is working to incorporate that detection into a developmental sequencing kit for Proteus instruments.
QSI · Quantum-Si Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 45%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Nov 2020 to Nov 2026
Up next
Latest documents
Quantum SI says Proteus remains on track for a second quarter 2027 launch, expects detection of the 20th amino acid before the end of the year, and has sufficient capital through the fourth quarter of 2028.
Quantum-Si reported nine-month revenue down 59.0% and net loss of $67.5 million, while an August 2026 restructuring terminated approximately 20% of its 152 employees. Proteus is estimated to launch in the second quarter of 2027.
Quantum-Si reported third-quarter revenue of $212,000, down from $552,000, as the Platinum-to-Proteus transition continued. Proteus remains on track for a Q2 2027 launch, while 2026 revenue guidance stayed at approximately $1.0 million and cash runway was reaffirmed into Q4 2028.
Quantum-Si regained compliance with Nasdaq's minimum bid price requirement as of October 13, 2026, closing the matter. The company will keep monitoring its bid price, and a future shortfall could again trigger delisting notice.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Quantum-Si pushed the Proteus launch from end of 2026 to Q2 2027 to add an extra integrated instrument design cycle, announced a ~20% workforce reduction expected to deliver ~$12M in annualized savings, and extended its cash runway into Q4 2028 while reiterating 2026 guidance.
- + Cash runway extended into Q4 2028 from Q2 2028 following cost actions
- + Management identifies a >$4B non-human proteomics market opportunity for Proteus
- + Strategic shift to application-oriented library prep kits expected to expand capabilities and reduce technical risk
- + Net loss narrowed to $23.5M in Q2 2026 from $28.8M in Q2 2025
- − Proteus launch pushed from end of 2026 to Q2 2027 to add an extra instrument design cycle
- − Q2 2026 revenue fell 42% YoY to $344K as Platinum-to-Proteus transition dampens demand
- − Q2 2026 gross margin of 50% impacted by mix and transition-period commercial activity; H1 2026 gross margin was 41%
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -58.18M | Nine months ended September 30, 2026 | — |
|
|
|||
| Adjusted total operating expenses non-GAAP | $62.1M | the nine months ended September 30, 2026 | — |
|
|
|||
| Cash, cash equivalents and investments in marketable securities | $149.4M | As of September 30, 2026 | — |
| EBITDA non-GAAP | -69.03M | Nine months ended September 30, 2026 | — |
|
|
|||
| Reduction in force | 20% | second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QSI
this stock
Quantum-Si Inc
|
$199.75M | -17.4% | -20.3% | — | 5.8% |
|
ABT
Abbott Laboratories
|
$178.39B | -17.8% | +5.7% | 38.4 | 1.1% |
|
MDT
Medtronic plc
|
$127.84B | +4.0% | +8.4% | 24.6 | 1.8% |
|
SYK
Stryker Corp
|
$118.01B | -11.8% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$60.85B | -56.0% | +12.5% | 17.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 20
Quantum-Si has demonstrated detection of all 20 naturally occurring amino acids in its Proteus development program, achieving its year-end 2026 goal ahead of schedule. It is working to incorporate that detection into a developmental sequencing kit for Proteus instruments.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QSI | -21.0% | -35.1% | -26.7% | -37.7% | -17.4% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -12.4% | -25.8% | -17.5% | -29.0% | -18.5% |